脂质体阿霉素 利妥昔单抗治疗老年b细胞淋巴瘤.pdfVIP

Leukemia Lymphoma, October 2006; 47(10): 2174 – 2180 ORIGINAL ARTICLE: CLINICAL CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 1 1 2 3 1 2 F. ZAJA , V. TOMADINI , A. ZACCARIA , M. LENOCI , M. BATTISTA , A. L. MOLINARI , A. FABBRI3 4 5 6 1 , R. BATTISTA , M. G. CABRAS , A. GALLAMINI , R. FANIN 1Division of Hematology, DIRM, University Hospital, Udine, Italy, 2Division of Hematology, Ravenna, Italy, 3Department of Hematology, University Hospital, Siena, Italy, 4Division of Hematology, Chioggia, Italy, 5Division of Hematology, Cagliari, Italy, and 6Division of Hematology, Cuneo, Italy (Received 27 February 2006; revised 4 May 2006; accepted 8 May 2006) Abstract Thirty untreated patients, median age 69 years (range 60 – 75 years), with diffuse large B-cell lymphoma (B-DLCL) were treated with a pegylated liposomal doxorubicin (PL-doxorubicin) modified CHOP-rituximab regimen. PL-doxorubicin 30 mg/m2, was given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses. Cardiac toxicity was evaluated by mean of echocardiography for left ventricular ejection fraction (LVEF) evaluations and serum troponin-I levels. Overall response and complete response rates were 76% and 59%. Projected two year event free survival and overall survival are 65.5% and 68.5%. No treatment-related mortality was documented. WHO grade III-IV neutropenia and thrombocytopenia were 86% and 3%. Extra-hematological III-IV toxicity was represented, respectively, by a single case of infection, mucositis, and bleeding. LVEF evaluations and the troponin levels did not show significant